IL246598B - Sustained-release pridopidine preparations - Google Patents

Sustained-release pridopidine preparations

Info

Publication number
IL246598B
IL246598B IL246598A IL24659816A IL246598B IL 246598 B IL246598 B IL 246598B IL 246598 A IL246598 A IL 246598A IL 24659816 A IL24659816 A IL 24659816A IL 246598 B IL246598 B IL 246598B
Authority
IL
Israel
Prior art keywords
pridopidine
release formulations
modified release
modified
formulations
Prior art date
Application number
IL246598A
Other languages
English (en)
Hebrew (he)
Other versions
IL246598A0 (en
Original Assignee
Prilenia Neurotherapeutics Ltd
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53543863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL246598(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prilenia Neurotherapeutics Ltd, Teva Pharmaceuticals Int Gmbh filed Critical Prilenia Neurotherapeutics Ltd
Publication of IL246598A0 publication Critical patent/IL246598A0/en
Publication of IL246598B publication Critical patent/IL246598B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
IL246598A 2014-01-22 2016-07-04 Sustained-release pridopidine preparations IL246598B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461930358P 2014-01-22 2014-01-22
US201462050626P 2014-09-15 2014-09-15
PCT/US2015/012248 WO2015112601A1 (en) 2014-01-22 2015-01-21 Modified release formulations of pridopidine

Publications (2)

Publication Number Publication Date
IL246598A0 IL246598A0 (en) 2016-08-31
IL246598B true IL246598B (en) 2021-01-31

Family

ID=53543863

Family Applications (2)

Application Number Title Priority Date Filing Date
IL246598A IL246598B (en) 2014-01-22 2016-07-04 Sustained-release pridopidine preparations
IL280485A IL280485B2 (en) 2014-01-22 2021-01-28 Sustained-release pridopidine preparations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL280485A IL280485B2 (en) 2014-01-22 2021-01-28 Sustained-release pridopidine preparations

Country Status (20)

Country Link
US (3) US20150202302A1 (enExample)
EP (2) EP3096759B1 (enExample)
JP (2) JP6949487B2 (enExample)
KR (1) KR102479759B1 (enExample)
CN (1) CN106170287A (enExample)
AU (1) AU2015209411A1 (enExample)
CA (1) CA2937243C (enExample)
CL (1) CL2016001874A1 (enExample)
DK (1) DK3096759T3 (enExample)
EA (1) EA201691454A1 (enExample)
ES (1) ES2911800T3 (enExample)
HU (1) HUE058288T2 (enExample)
IL (2) IL246598B (enExample)
MX (1) MX377576B (enExample)
PE (1) PE20161220A1 (enExample)
PL (1) PL3096759T3 (enExample)
TW (1) TW201605446A (enExample)
UA (1) UA122053C2 (enExample)
UY (1) UY35962A (enExample)
WO (1) WO2015112601A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SG10201506761XA (en) 2010-09-03 2015-10-29 Teva Pharmaceuticals Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
MX384234B (es) 2013-06-21 2025-03-14 Prilenia Neurotherapeutics Ltd Uso de pridopidina para el tratamiento de enfermedad de huntington.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US20150202302A1 (en) 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2017015615A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
DK3503890T3 (da) * 2016-08-24 2025-01-27 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af dystonier
BR112019003732A2 (pt) 2016-08-24 2020-02-18 Prilenia Therapeutics Development Ltd. Aplicação de pridopidina para tratamento de declínio funcional
US12102627B2 (en) * 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
MX388845B (es) 2016-09-16 2025-03-20 Prilenia Neurotherapeutics Ltd Uso de pridopidina para tratar el sindrome de rett.
JP7114604B2 (ja) 2017-01-20 2022-08-08 プリレニア ニューロセラピューティクス リミテッド 脆弱ｘ症候群の治療のためのプリドピジンの使用
DK3668509T3 (da) 2017-08-14 2023-02-20 Prilenia Neurotherapeutics Ltd Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin
MX2020002310A (es) * 2017-08-30 2020-09-17 Prilenia Neurotherapeutics Ltd Formas de dosificacion de alta concentracion de pridopidina.
CN111343982A (zh) 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 用于治疗药物诱发的异动症的普利多匹定
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
KR20200056071A (ko) 2018-11-14 2020-05-22 한화토탈 주식회사 내열성, 강성 및 용융 강도가 우수한 폴리올레핀 수지 조성물
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150406A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH Hydrobromide salt of pridopidine
US20130267552A1 (en) * 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4020983B2 (ja) * 1995-07-07 2007-12-12 帝國製薬株式会社 持続性製剤およびその製法
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
KR20030019326A (ko) 2000-03-21 2003-03-06 니뽄 신야쿠 가부시키가이샤 방출 제어형 경구 투여 제제
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
GB0125088D0 (en) 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
AU2004268663B2 (en) * 2003-09-02 2010-12-09 Pfizer Products Inc. Sustained release dosage forms of ziprasidone
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
MX384234B (es) * 2013-06-21 2025-03-14 Prilenia Neurotherapeutics Ltd Uso de pridopidina para el tratamiento de enfermedad de huntington.
US20150202302A1 (en) 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150406A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH Hydrobromide salt of pridopidine
US20130267552A1 (en) * 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTIN MICHL ET AL,, PRIDOPIDINE IN THE PHARMACOLOGICAL TREATMENT OF HUNTINGTON'S DISEASE, 1 July 2013 (2013-07-01) *

Also Published As

Publication number Publication date
EA201691454A1 (ru) 2017-01-30
UA122053C2 (uk) 2020-09-10
EP3096759A4 (en) 2017-08-02
IL280485A (en) 2021-03-01
IL280485B1 (en) 2023-01-01
HUE058288T2 (hu) 2022-07-28
IL246598A0 (en) 2016-08-31
TW201605446A (zh) 2016-02-16
JP2017503823A (ja) 2017-02-02
JP6949487B2 (ja) 2021-10-13
KR20160125385A (ko) 2016-10-31
US20190209542A1 (en) 2019-07-11
ES2911800T3 (es) 2022-05-20
PL3096759T3 (pl) 2022-06-13
EP3096759A1 (en) 2016-11-30
IL280485B2 (en) 2023-05-01
US20240041855A1 (en) 2024-02-08
US20150202302A1 (en) 2015-07-23
MX377576B (es) 2025-03-04
CN106170287A (zh) 2016-11-30
WO2015112601A1 (en) 2015-07-30
MX2016009427A (es) 2016-12-08
KR102479759B1 (ko) 2022-12-21
CL2016001874A1 (es) 2017-05-12
AU2015209411A1 (en) 2016-09-01
JP7266298B2 (ja) 2023-04-28
DK3096759T3 (da) 2022-05-09
CA2937243A1 (en) 2015-07-30
EP4049657A1 (en) 2022-08-31
UY35962A (es) 2015-08-31
PE20161220A1 (es) 2016-11-23
JP2020023518A (ja) 2020-02-13
EP3096759B1 (en) 2022-04-06
CA2937243C (en) 2023-07-18

Similar Documents

Publication Publication Date Title
IL280485A (en) Sustained-release pridopidine preparations
IL250511A0 (en) Crystalline forms of ibrutinib
PL3137060T5 (pl) Kompozycje zawiesinowe o przedłużonym uwalnianiu
PL3099381T3 (pl) Kompozycje środków zapachowych o przedłużonym uwalnianiu
PT3102555T (pt) Composições de compostos e seus usos
GB201404139D0 (en) Sustained release buprenorphine solution formulations
IL252062A0 (en) Transdermal compositions
SI3845221T1 (sl) Trdne oblike sofosbuvirja
GB201419091D0 (en) Formulations
PT3474822T (pt) Formulações de brincidofovir
IL248223B (en) Compositions of vaccine
PL3223837T3 (pl) Lactobacillus do zastosowania jako probiotyk
GB201419261D0 (en) Formulations
IL246979A0 (en) Crystalline forms of sofosbuvir
SG11201803156TA (en) Sustained release formulations of local anesthetics
PT3142641T (pt) Formulações para o tratamento de hipertiroidismo
IL247828A0 (en) Progesterone compounds
IL246569A0 (en) Solid forms of tenofovir
IL249130B (en) Preparation of piperidine-4-carbothioamide
TWI561205B (en) Quick release structure of electrosurgical unit
HK1228789A1 (en) Modified release formulations of pridopidine
IL249332A0 (en) Crystalline forms of sofosbuvir
GB201412359D0 (en) Composition of objects
GB201412089D0 (en) Composition of objects
GB201418410D0 (en) use of compositions of matter

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed